Investment Bank Cowen and Company, which initiated coverage on the cannabis industry in September, is hosting a gathering of institutional investors in New York City on January 12th. Several public company executives will be participating on panels, including Nick Kovacevich of Kush Bottles (OTC: KSHB) and Brett Roper of Medicine Man Technologies (OTC: MDCL), who will take part in a discussion entitled “Seed to Sale” along with Sally Vander Veer, President of Medicine Man and Ben Kaanta, Director of Operations at MJardin, which provides turnkey cannabis cultivation management in ten states. Cowen initiated coverage on Kush Bottles in September, giving the company a ‘Buy’ rating and a target price of $3 per share.
The morning begins with an introduction by Vivien Azer, Managing Director, Lead Beverage, Tobacco & Cannabis Analyst followed by a panel on U.S. policy, with Allen St. Pierre, Jeffrey Friedland and Michael Safir participating. Cy Scott, the CEO of Headset, will discuss consumer insights and will be followed by Brendan Kennedy of Privateer Holdings. Ethan Nadelmann of Drug Policy Alliance is the luncheon speaker.
In the afternoon, Mark Whitmore of Deloitte Private will discuss the market opportunity in Canada. The CEOs of three Canadian licensed producers will follow, with Bruce Linton of Canopy Growth (TSX: CGC) (OTC: TWMJF), Denis Arsenault of OrganiGram (TSXV: OGI) (OTC: OGRMF) and Michael Gorenstein of The Cronos Group (TSXV: MJN) (OTC: PRMCF), previously PharmaCan Capital, participating in a panel discussion. In November, Canopy Growth engaged Cowen and Company for investment banking services.
The last panel, which addresses technology, includes Mark Grindeland of Coda Signature, Lynn Honderd of Mary’s Medicinals and Tyler Goldman, the new CEO at PAX Labs. The event is by invitation-only for clients and guests of Cowen and Company.
Before this cannabis stock news is here, it's published to subscribers on 420 Investor.
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV.
Contact Alan: Twitter | Facebook | LinkedIn | Email